Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, Fruttero R, Gasco A, Bronte V, Viola A.

J Exp Med. 2011 Sep 26;208(10):1949-62. doi: 10.1084/jem.20101956. Epub 2011 Sep 19.

2.

Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.

Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, Silva-Santos B.

J Immunol. 2013 Jun 15;190(12):6673-80. doi: 10.4049/jimmunol.1300434. Epub 2013 May 17.

3.

Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D.

Eur J Immunol. 2006 Feb;36(2):457-67.

4.

Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.

Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC.

J Immunol. 2007 Sep 1;179(5):3332-41.

5.

EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.

Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K, Batra RK, Strieter RM, Dubinett SM, Sharma S.

J Immunol. 2003 Dec 15;171(12):6457-65.

6.

Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.

Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, Vergnon I, Mackiewicz A, Benihoud K, Validire P, Chouaib S, Combadière C, Mami-Chouaib F.

Cancer Res. 2009 Aug 1;69(15):6249-55. doi: 10.1158/0008-5472.CAN-08-3571. Epub 2009 Jul 28.

8.

Hiding the road signs that lead to tumor immunity.

Schaer DA, Lesokhin AM, Wolchok JD.

J Exp Med. 2011 Sep 26;208(10):1937-40. doi: 10.1084/jem.20111856. Review.

9.

Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.

Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, Wang LC, Singhal S, Snyder LA, Albelda SM.

Am J Respir Cell Mol Biol. 2011 Feb;44(2):230-7. doi: 10.1165/rcmb.2010-0080OC. Epub 2010 Apr 15.

10.

CCL2 blockade augments cancer immunotherapy.

Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM.

Cancer Res. 2010 Jan 1;70(1):109-18. doi: 10.1158/0008-5472.CAN-09-2326. Epub 2009 Dec 22. Erratum in: Cancer Res. 2010 Mar 15;70(6):2569. Crisanti, Cecilia [corrected to Crisanti, M Cecilia].

11.

MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.

Grosso JF, Herbert LM, Owen JL, Lopez DM.

J Immunol. 2004 Aug 1;173(3):1721-30.

12.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

13.

Effects of intratumoral injection of CCL2 on monocyte-endothelial cell interactions in mouse pancreatic cancer.

Okudaira K, Tsuzuki Y, Hokari R, Miyazaki J, Mataki N, Komoto S, Okada Y, Kawaguchi A, Nagao S, Itoh K, Miura S.

Microcirculation. 2007 Apr-May;14(3):241-51.

PMID:
17454676
15.

Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.

Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.

Clin Cancer Res. 2008 Oct 15;14(20):6487-95. doi: 10.1158/1078-0432.CCR-08-1086.

16.

Mesenchymal contribution to recruitment, infiltration, and positioning of leukocytes in human melanoma tissues.

Samaniego R, Estecha A, Relloso M, Longo N, Escat JL, Longo-Imedio I, Avilés JA, del Pozo MA, Puig-Kröger A, Sánchez-Mateos P.

J Invest Dermatol. 2013 Sep;133(9):2255-64. doi: 10.1038/jid.2013.88. Epub 2013 Feb 27.

17.

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.

Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, Hooijberg E, Schumacher TN, Haanen JB, Spits H, Luiten RM.

Cancer Res. 2004 Mar 15;64(6):2153-61.

19.
Items per page

Supplemental Content

Write to the Help Desk